EUROTAU London, UK, April 24-25, 2025
Welcome to the Eurotau meetings
Eurotau 2025 will be held in London, UK
on April 24-25, 2025
Part of the Global Tau conference (Alzheimer Association, Cure PSP, Eurotau & the Rainwater Prize)
Worldwide scientists involved in Tau research meet in Lille to exchange new ideas and hypotheses on physiological and pathological roles of tau proteins.
EUROTAU
London, UK, April 24-25, 2025
Welcome to the Eurotau meetings
Eurotau 2025 will be held in London, UK
on April 24-25, 2025
Part of the Global Tau conference (Alzheimer Association, Cure PSP, Eurotau & the Rainwater Prize)
Worldwide scientists involved in Tau research meet in Lille to exchange new ideas and hypotheses on physiological and pathological roles of tau proteins.
https://eurotau.fr/
EUROTAU
London, UK, April 24-25, 2025
Programme
Open menu
Topics
Venue
Sponsors 2023
Who are we?
Eurotau meetings
Open menu
Video
List of titles of eurotau abstracts
List of speakers
More to come…
Frank Bennett, Ionis, USA
Don Cleveland, UC San Diego, USA
Ilse Dewachter, Hasselt, Belgium
ApoE, inflammation and tau in AD: a road towards multi-targeted therapies
Stephanie Fowler, London, UK
Short tau filaments are packaged into extracellular vesicles in AD brain
Michel Goedert, Cambridge, UK
Cryo-EM structures of amyloid filaments from human brains
Maud Gratuze, Marseille, France
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4
Jürgen Götz, Brisbane, Australia
Tau in Alzheimer’s disease – from pathomechanistic studies to therapeutic ultrasound as a treatment modality
Bernard Hanseeuw, Louvain, Belgium
Specific post-translational modifications of the soluble tau protein distinguish between Alzheimer’s disease, 4R-, and 3R-tauopathies
Eckhard Mandelkow, Germany
Pierre Maquet, Liège, Belgium
Early brainstem tau relates to cortical excitability in healthy aging
Ana Melo de Farias, Brazil & France
Alzheimer’s risk gene PTK2B effects TAU phosphorylation in human induced neurons
Tim Miller, MO, USA
Leonard Petrucelli, FL, USA
TMEM106b in FTLD-TDP and PSP
Naruhiko Sahara, Inage, Chiba, Japan
Dissecting mechanisms of tauopathy using in vivo multimodal imaging techniques on tauopathy mouse models
Wiep Scheper, Amsterdam, NL
Understanding Granulovacuolar Degeneration Bodies: A neuron-specific response to tau pathology
Maria Grazia Spillantini, Cambridge, UK
Glial cells in P301S tau transgenic mice show ageing-related features
Patrik Verstreken, Leuven, Belgium
Tau toxicity at the synapse
Susanne Wegmann, Berlin, Germany
Tau aggregation and liquid droplets
Claude Wischik, TauRx
Phase 3 outcomes for tau aggregation inhibitor in Alzheimer’s
Title of Eurotau abstracts
A 3D human co-culture to model neuron-astrocyte interactions in tauopathies
A brain-seeded fibril amplification models the aggregation process of tau in Alzheimer’s disease for drug discovery
A direct CSF-to-blood Tau transport: the tanycytic clearance.
A natural variant of the autophagic receptor NDP52 as a new target for Alzheimer’s Disease
A new mechanism of endogenous Tau aggregation through ApoE/neuroproteasome complexes
Alzheimer’s risk gene PTK2B affects TAU phosphorylation in human induced neurons
Analysis of neurofilament light alterations in brain versus blood in TauP301S and 5xFAD mice.
Analysis of the molecular factors driving neuronal pathology in Alzheimer’s Disease using GeneFunnel, a novel gene set enrichment and network analysis tool
Anti-S100B nanobodies as modulators of Tau aggregation
APOE deficiency rescues tau pathology and tau driven neurodegeneration in P301S mouse model
ApoE, inflammation and tau in AD: a road towards multi-targeted therapies.
Chaperone modulation of tau aggregation and condensation
Chaperone regulation of tau liquid-liquid phase separation
Characterizing the interaction between Tau and tubulin using SDL-EPR spectroscopy
CK1δ activity is required for the accumulation of tau-induced granulovacuolar degeneration bodies
Consequences of a high-fat diet during lactation in a mouse model of tauopathy
Contribution of phosphorylation and aggregation to Tau-mediated toxicity.
Cryo-EM Structures of Amyloid Filaments from Human Brains
Developing the Drosophila wing disc as a model system of Tau internalization and trafficking
Development of an AAV-based model of tauopathy targeting the dentate gyrus to study the role of microglia in the spreading of toxic tau species
Differential implication of large and small extracellular vesicles in tau seeding
Dissecting mechanisms of tauopathy using in vivo multimodal imaging techniques on tauopathy mouse models
Dual Optical Techniques to Study Liquid-Liquid Phase Separation of Tau
Early brainstem tau relates to cortical excitability in healthy aging
Effects of adenosine A2A receptor astrocytic upregulation in the mouse hippocampus
Effects of spermidine on tau-induced mitochondrial dysfunction
Elucidating key components in Alzheimer’s disease progression.
Enriched environment- non-pharmacological alternative to slow down propagation of AD tau pathology and improve cognitive functions
Evaluation of astrocytes morphological changes in tauopathies
Extracellular tau impairs the interaction of tau with microtubules in model neurons: A new cellular model for understanding tauopathies
Free cholesterol regulates neuronal pTau
From early endosomal deficits to severe dendrite collapse: tau pathology in human and mouse neurons
Frontotemporal dementia-associated tau mutations induce altered nucleolar structure before cell death
Glutamatergic drivers of Tau pathology in the human thalamus
High amount and fast production of tauc3 in ps19 mice
How does insulin resistance increase risk of Alzheimer’s disease?
Human MAPT knock-in mice that harbor familial tauopathy-causing mutations
Human Tau aggregates are permissive to Protein Synthesis Dependent Memory in Drosophila Tauopathy models
Human tau-isoform specific effects in Drosophila CNS
Hydromethylthionine first, rivastigmine second: cognitive effects of single versus combination therapies in tau transgenic mice
Hydromethylthionine induces long-term and sustained decreases in truncated tau in a mouse model of frontotemporal dementia
Identify critical regulators of pre-synaptic tau release
Impact of tau and amyloid-beta lesions on the transcriptome expression in a primate model of Alzheimer’s Disease.
Impact of tau on the ER-mitochondria coupling
Impact of Tau protein on the nuclear envelope and chromatin structure
In vitro aggregation of tau by protein misfolding cyclic amplification
In vitro and in vivo artefacts when analysing tau phosphorylation by Western blot or immunohistochemistry.
In vivo modulation of Tau pathology and neurodegeneration by NLRP3 inflammasome
Interaction between Tau and nuclear transport proteins in Tau protein-associated dementias
Interaction of Alzheimer’s disease genetic risk factors: Characterization of PYK2 AND BIN1 protein-protein interaction
Interaction of tau and Aβ in mouse models of Alzheimer’s disease
Intraneuronal tau aggregation induces the integrated stress response in astrocytes
Investigating BIN1 involvement in tau handling and extracellular vesicle secretion in iPSC-microglia
Investigating role of plumbagin in preventing neurodegenerative diseases via inhibiting the tau phosphorylating kinase MARK4
Investigating the contribution of an intronic variation at the TRIM11/TRIM17 locus to pathological and clinical heterogeneity in Progressive Supranuclear Palsy
Investigating the endocytic mechanism of pathological tau at the synapse
Investigating the pathological role of Tau associated with Alzheimer’s disease on the nucleolus of neuronal (SH-SY5Y) cells
Investigating the potential of the insulin-sensitizing drug Metformin in ameliorating Tau pathology in cellular and Drosophila models
Investigating the role of ERK, JNK and p38 in the phosphorylation of Thr175 tau associated with traumatic brain injury.
Investigating the synaptic mechanisms of the spread of wild type and P301S 1N4R human tau in in vitro and in vivo models
Isoform-specific siRNAs: A potential therapeutic approach for 4R tauopathies.
Isolation of spontaneously-released brain extracellular vesicles: implications for brain pathology
Lewy body co-pathology contributes to frontal lobe atrophy in Alzheimer’s disease and primary age-related tauopathy (PART)
Live-cell visualization of tau aggregation in human neurons
Local tau reduction rescues pathological phenotypes in a preclinical model of tauopathy
MAPT mutations in Amyotrophic Lateral Sclerosis
MAPT S305 mutations alter neuron and astrocyte function
Mass-spectrometry analysis of a tau hyperphosphorylation model reveals increased stathmin-2 expression as an inducer of microtubule destabilization
Methods to assess the activity of drug candidates on tau aggregation and tau microtubule dynamics
Mical modulates Tau toxicity via cysteine oxidation in vivo
Mutations in tau protein influence aggregation propensity through conformation modulation
NanoBit tau biosensors bring new insights into the molecular events triggering early pathological tau transformation and seeding activity
NanoTarget : An original approach for intracellular delivery of anti-tau single domain antibodies
Neuronal identity defines a-synuclein and tau toxicity
Neuronal vulnerability to tau-mediated toxicity is characterized by a broad spectrum of varying responses
Neuroprotective effects of CB2 cannabinoid receptor antagonists’ treatment in TAU-dependent Frontotemporal Dementia
New Thiazole-Flavone Hybrid Compounds Binding to Tau Protein and With Antitumor Activity Against Glioblastoma
Oligomerization of Tau on Microtubules
Optimization and selection of VHHs targeting Tau nucleation core
Pathogenic Tau reactivates a developmental pruning pathway
Peptide-based inhibitors of Tau aggregation as a potential therapeutic for Alzheimer’s disease and other Tauopathies
Persistent pain causes Tau-mediated hippocampal malfunction and memory deficits
Phase 3 outcomes for tau aggregation inhibitor in Alzheimer’s
Phase separation of a paired-helical filament forming region of tau
Phosphorylated tau is present in the human nucleus incertus of the brain
Physicochemical characterization of cellular Tau accumulations and aggregates using advanced imaging modalities
Presynaptic toxicity of the ad risk gene bin1
Protection against tauopathy is influenced by sex
Proteomic signature of vulnerable neurons in Alzheimer’s disease brains
Purinergic P2Y12 receptor-mediated endocytic accumulation of Tau oligomers with β-arrestin-1 and follow lysosomal degradation in microglia
Pyk2 and Tau interaction promotes synaptic localization of phospho-Tau 181/Tau in neurons
Regulation of Tau protein phosphorylation by kinase O-GlcNAcylation and its implication in fibrillar aggregation
Revisiting the involvement of tau in complex neural network remodelling: analysis of the extracellular neuronal activity in organotypic brain slice co-cultures
Screening tyrosine kinases for their involvement in synaptotoxicity induced by tau microtubule-binding region fibrils
Short tau filaments are packaged into extracellular vesicles in AD brain
Silencing of phagocytic receptor MERTK in astrocytes alleviates Tau pathology in rodent models of primary Tauopathies
Specific tau PTMs distinguish AD, 4R &3R tauopathy
Study of the brain-gut axis in a mouse model of Alzheimer’s disease
Study of the interactions between the Alzheimer’s disease genetic risk factors BIN1 and PTK2B
Synaptogyrin-3: A potential target against Tau-induced pre-synaptic defects?
Targeting intracellular tau with intrabodies
Targeting of pathological tau protein in interstitial fluid using anti-PHF6 minibody
Tau aggregation and liquid droplets
Tau biology, tau vaccines and therapeutic ultrasound
Tau secretion is driven by circadian variations of body temperature during the sleep/wake cycle: implications for tau spreading in Alzheimer’s disease
Tau toxicity at the synapse
Tauopathy-associated PERK variants impair signal transduction and promote tau aggregation
Temperature and Concentration Dependent Alteration in Tau Liquid–liquid Phase Separation through Hyperphosphorylation
The effect of the ApoE Christchurch mutation on AD pathology in a combined amyloid and tau mouse model
The role of human microglia and microglial LRRK2 in tau pathogenesis
The role of tau isoforms in neuronal vulnerability
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4
Ubiquitination as a modulator of tau aggregation and condensation
Understanding Granulovacuolar Degeneration Bodies: A neuron-specific response to tau pathology
Understanding Granulovacuolar Degeneration Bodies: A neuron-specific response to tau pathology
Validation of an AD brain seed-injection model in hTau mice
Validation of therapeutic siRNAs in hiPSCs-derived neurons, a model of FTDP-17
Visualization of tau pathology using in situ cryo-ET
Zika virus infection of immunocompetent mice leads to a persistent disease associated microglia (DAM)-like phenotype and the pathological phosphorylation of Tau protein.
